S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p).
Paolo Strati,Michael J. Keating,Susan O'Brien,Alessandra Ferrajoli,Jan A. Burger,Stefan Faderl,Nitin Jain,William G. Wierda +7 more
TL;DR: Outcomes for first-line treatment of del17p CLL with relapsed CLL bearing del 17p are summarized and age >65 yrs, complex kary...
Journal ArticleDOI
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
David A. Rizzieri,Gary J. Schiller,Scott R. Solomon,Laura F. Newell,Harry P. Erba,Robert J. Ryan,Stefan Faderl,Jorge E. Cortes,Jeffrey E. Lancet +8 more
TL;DR: In a phase 3 study in older patients with newly diagnosed high-risk/secondary AML, CPX-351 significantly improved OS vs 7+3, with a comparable safety profile, and improved median OS overall and OS landmarked from the HCT date vs 7-3.
Journal ArticleDOI
The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.
Alessandra Ferrajoli,Yongtao Wang,Susan O'Brien,Stefan Faderl,David Harris,Quin Van,Inbal Hallevi,Zhiming Liu,Patricia E. Koch,John Sensintaffar,Francis Burrows,Hagop M. Kantarjian,Michael J. Keating,Zeev Estrov +13 more
TL;DR: The data suggest that EC141 degrades the Bcr-Abl p190 protein, inhibits proliferation, and induces apoptosis of Ph+ ALL cells.
Journal ArticleDOI
Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center
Farshid Dayyani,Sarah Schellhorn Mougalian,Kiran Naqvi,Farhad Ravandi,Jorge E. Cortes,Elias Jabbour,Stefan Faderl,William G. Wierda,Deborah A. Thomas,Susan O'Brien,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +12 more
TL;DR: The clinical characteristics of a large cohort of contemporary pts who developed ICH at MD Anderson Cancer Center (MDACC) to help better define the characteristics of pts at risk are evaluated, indicating that the major cause for developing ICH is chemotherapy-related thrombocytopenia or relapsed disease.
Journal ArticleDOI
WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL.
Alessandra Ferrajoli,Stefan Faderl,Tony Wang,Waldemar Priebe,Hagop M. Kantarjian,Moshe Talpaz,Zeev Estrov +6 more
TL;DR: The data suggest that exposure to WP1066 induces caspase-dependent apoptosis, is associated with PI3-K inhibition and reduces the growth of the Ph+ cell lines Z-119 and Z-181.